December 18, 2017 / 1:25 PM / a month ago

BRIEF-Fda Accepts Biologics License Application For Fremanezumab With Priority Review

Dec 18 (Reuters) - Teva Pharmaceutical Industries Ltd :

* FDA ACCEPTS BIOLOGICS LICENSE APPLICATION FOR FREMANEZUMAB WITH PRIORITY REVIEW FOR PREVENTION OF MIGRAINE AND GRANTS FAST TRACK DESIGNATION FOR CLUSTER HEADACHE DEVELOPMENT PROGRAM

* TEVA PHARMACEUTICAL INDUSTRIES - TEVA ANTICIPATES LAUNCHING ANTI-CGRP PRODUCT IN U.S. FOR PREVENTION OF MIGRAINE IN 2018

* TEVA PHARMACEUTICAL INDUSTRIES - FREMANEZUMAB ACHIEVED STATISTICALLY SIGNIFICANT RESULTS ACROSS ALL TRIAL ENDPOINTS

* TEVA PHARMACEUTICAL INDUSTRIES LTD - STUDIES FOR PHASE III ENFORCE CLINICAL RESEARCH PROGRAM ARE EXPECTED TO CONCLUDE IN EARLY 2019

* TEVA PHARMACEUTICAL INDUSTRIES - CO HAS ALSO INITIATED A FREMANEZUMAB PHASE II CLINICAL PROGRAM FOR TREATMENT OF POST-TRAUMATIC HEADACHE DISORDER Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below